Westlake Village, CANCT06343298Now EnrollingIRB Ready

Resistant Hypertension Clinical Trial in Westlake Village, CA

Access cutting-edge resistant hypertension treatment through this phase 2 clinical trial at a research site in Westlake Village. Study-provided care at no cost to qualified participants.

Sponsored by E-Star BioTech, LLC

Quick Self-Assessment

See if you qualify for this Westlake Village location

Preparing your pre-screening questions…

Expert Care in Westlake Village

Access resistant hypertension specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related resistant hypertension treatment provided free

Apply for This Westlake Village Location

Check if you qualify for this resistant hypertension clinical trial in Westlake Village, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Westlake Village

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Westlake Village site if eligible
  4. 4Begin participation

About This Resistant Hypertension Study in Westlake Village

This is a Phase 2 dose-titration study designed to evaluate the safety and efficacy of MANP subcutaneous injection compared to placebo in reducing baseline daytime systolic blood pressure (SBP), derived from 24-hour ambulatory blood pressure monitoring (ABPM), in subjects with hypertension who are taking 3 or more antihypertensive medications with different mechanisms of action.

Sponsor: E-Star BioTech, LLC

Who Can Participate

Inclusion Criteria

Subjects will be eligible for enrollment in the study only if they meet ALL the following criteria at time of Screening:
Male or female subjects aged 18 - 80 years, inclusive, at the screening visit.
Female subjects must not be of childbearing potential
Subjects must be taking appropriate doses of 3 or more antihypertensive drugs with different mechanisms of action. One of which must be a diuretic and the other must be an ACEi or ARB at atleast 50% of the maximum recommended dose for hypertension.
Subjects must have a seated (5 minutes) systolic blood pressure ≥ 140 mmHg and SBP ≥135 mmHg by ABPM prior to randomization (T1).
Subjects must have a CKD-EPI eGFR ≥ 30 mL/min/1.73m2
A subset of the subjects with an eGFR between 20-30 ml/min/1.73m2 will be included, not to exceed 10% of the total study subjects.
Subjects must have a BMI between 18 - 40 kg/m2.
Subjects who engage in sexual intercourse in which their partner could become pregnant must agree to use a barrier method of birth control (i.e., vaginal/penile condom) with spermicide for the duration of the study and for 90 days after the last dose of study drug or be at least 6 weeks post-vasectomy with confirmation by post-vasectomy semen analysis. In addition, subjects may not donate sperm for the duration of the study and for 90 days after the last dose of study drug.

Exclusion Criteria

Subjects meeting ANY of the following criteria at time of Screening will be excluded from enrollment:
Subjects with an average sitting systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥ 110 mmHg at Screening (SV), or prior to randomization at T1.
Subjects with a history of secondary hypertension, including but not limited to coarctation of the aorta, primary hyperaldosteronism, renal artery stenosis, Cushing's disease, pheochromocytoma, and polycystic kidney disease. If the subject has not previously been evaluated for secondary hypertension, investigators are responsible for evaluating all potential secondary causes of hypertension in accordance with current practices and clinical guidelines before entering the patient into the study.
Subjects with an HbA1c ≥ 8% at screening (SV)
Subjects who have experienced myocardial infarction, unstable angina, or a cerebrovascular accident (CVA) within 6 months of the Screening Visit; or sick sinus syndrome or second- or third-degree atrioventricular block, or recurrent atrial tachyarrhythmia, recurrent ventricular tachycardia, or symptomatic bradycardia.
Subjects who have an implanted cardioverter defibrillator (ICD) that has been fired for any arrhythmia within 3 months of Screening (SV) or implanted pacemakers.
Subjects with congestive heart failure (New York Heart Association \[NYHA\] class II-IV)
Subjects with hemodynamically significant valvular heart disease
Subjects undergoing hemodialysis or peritoneal dialysis, or history of renal transplant.
Subjects who have diagnosis or recurrence of malignancy within the past 3 years
Subjects with a documented history of sleep apnea, with a prescription for CPAP therapy.
Women of childbearing potential
Subjects who are pregnant or breastfeeding

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Westlake Village?

Yes, this clinical trial (NCT06343298) has an active research site in Westlake Village, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Resistant Hypertension Treatment Options in Westlake Village, CA

If you're searching for resistant hypertension treatment options in Westlake Village, CA, this clinical trial (NCT06343298) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Westlake Village research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced resistant hypertension specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all resistant hypertension clinical trials near you to find additional studies recruiting in your area.

More Hypertension Trials in Westlake Village, CA

See all hypertension clinical trials recruiting in Westlake Village — not just this study.

Browse Hypertension Trials in Westlake Village →

Browse More Trials by Condition

Hypertension TrialsPulmonary Embolism TrialsAll Conditions →

Ready to Join in Westlake Village?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Westlake Village, CA